Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.7
3.2
Journals
Life
Special Issues
Immunotherapy in Lung Cancer and Biomarkers of Response
share announcement

Immunotherapy in Lung Cancer and Biomarkers of Response

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: closed (15 March 2023) | Viewed by 4828

Special Issue Editors

Dr. Hugo Arasanz Esteban

E-Mail Website
Guest Editor
Oncoimmunology Group, Navarrabiomed, 31008 Pamplona, Spain
Interests: programmed death-1 Ligand-1 (PDL1); checkpoint; tumor associated leukocyte
Special Issues, Collections and Topics in MDPI journals
Dr. Luisa Chocarro

E-Mail Website
Guest Editor
Oncoimmunology Group, Navarrabiomed, Fundación Miguel Servet-Complejo Hospitalario de Navarra UPNA-IdISNA, 31008 Pamplona, Spain
Interests: oncology; immunotherapy; immune checkpoints; molecular biology; CAR-T cells; adoptive cell transfer; nanobodies; lung cancer

Special Issue Information

Dear Colleagues,

Due to the development of immune checkpoint inhibitors, the treatment of lung cancer has experienced a radical change during the last several years, and relevant advances to replace the standard of care are presented every few months. However, the majority of patients do not respond to treatment, and the predictive biomarkers proposed thus far are lacking in accuracy. Furthermore, the mechanistics are not yet clear, and although CD4 and CD8 T cells are considered key players, other cells and molecules might strongly condition the response to immunotherapy. These are unmet needs on which basic and clinical research is spending great effort.

In addition, other immunotherapeutic treatments, such as vaccines, antibody-based targeted therapies and adoptive therapies, are being investigated for this disease, and outcomes from small non-randomized trials indicate the feasibility and potential of these approaches.

This Special Issue intends to gather work regarding advances in the mechanistics of immunotherapy in NSCLC, as well as novel approaches for the treatment of this disease.

Dr. Hugo Arasanz Esteban
Dr. Luisa Chocarro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • NSCLC
  • immunotherapy
  • biomarkers
  • checkpoint

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

21 pages, 589 KiB  
Review
TIGIT in Lung Cancer: Potential Theranostic Implications
by Carlo Pescia, Giuditta Pini, Edoardo Olmeda, Stefano Ferrero and Gianluca Lopez
Life 2023, 13(4), 1050; https://doi.org/10.3390/life13041050 - 19 Apr 2023
Cited by 2 | Viewed by 2070
Abstract
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, [...] Read more.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a co-inhibitory receptor expressed on various immune cells, including T cells, NK cells, and dendritic cells. TIGIT interacts with different ligands, such as CD155 and CD112, which are highly expressed on cancer cells, leading to the suppression of immune responses. Recent studies have highlighted the importance of TIGIT in regulating immune cell function in the tumor microenvironment and its role as a potential therapeutic target, especially in the field of lung cancer. However, the role of TIGIT in cancer development and progression remains controversial, particularly regarding the relevance of its expression both in the tumor microenvironment and on tumor cells, with prognostic and predictive implications that remain to date essentially undisclosed. Here, we provide a review of the recent advances in TIGIT-blockade in lung cancer, and also insights on TIGIT relevance as an immunohistochemical biomarker and its possible theranostic implications. Full article
(This article belongs to the Special Issue Immunotherapy in Lung Cancer and Biomarkers of Response)
►▼ Show Figures

Figure 1

11 pages, 574 KiB  
Review
Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy
by Alfredo Tartarone, Rosa Lerose, Marina Tartarone and Michele Aieta
Life 2022, 12(12), 2104; https://doi.org/10.3390/life12122104 - 14 Dec 2022
Cited by 5 | Viewed by 1801
Abstract
Lung cancer, of which non-small-cell lung cancer (NSCLC) represents about 80% of all cases, is the second most common cancer diagnosed in the general population and one of the major causes of cancer-related deaths worldwide. Overall, the outcomes of patients with advanced NSCLC [...] Read more.
Lung cancer, of which non-small-cell lung cancer (NSCLC) represents about 80% of all cases, is the second most common cancer diagnosed in the general population and one of the major causes of cancer-related deaths worldwide. Overall, the outcomes of patients with advanced NSCLC are still disappointing despite advances in diagnosis and treatment. In recent years immune-checkpoint inhibitors (ICIs), administered alone or in combination with chemotherapy, have revolutionized the treatment landscape of patients with advanced non-small-cell lung cancer. However, until now, tissue expression of PD-L1 and tumor mutation burden represent the only available biomarkers for NSCLC patients treated with ICIs. A growing body of evidence showed that tumor-derived exosomes (TDEs) have the PD-L1 protein on their surface and that they are involved in angiogenesis, tumor growth, invasion, metastasis and immune escape. This review focused on the potential clinical applications of TDEs in NSCLC, including their possible role as a biomarker for prognosis and disease monitoring in patients undergoing immunotherapy. Full article
(This article belongs to the Special Issue Immunotherapy in Lung Cancer and Biomarkers of Response)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop